← back to search

Patrick Masson

Centre Hospitalier de Lens · RU
Area of research
Pharmacology · Computational Theory and Mathematics
Research interest
Research interests include Cholinesterase and Neurodegenerative Diseases, Computational Drug Discovery Methods, Pesticide Exposure and Toxicity, and Pesticide and Herbicide Environmental Studies.
h-index
62
citations
15,104
works
521
NIH funding
primary concept
Chemistry
email

Recent publications

Innate and adaptive immune responses to the injection of hybrid camouflaging erythrocyte Saccharolobus solfataticus-phosphotriesterase mutant-loaded nanoreactors to mice.
2026cited by 0position: contributordoi
Kinetic and molecular modelling analyses of butyrylcholinesterase activity toward 'inverse' substrates.
2026cited by 0position: contributordoi
New views on physiological functions and regulation of butyrylcholinesterase and potential therapeutic interventions.
2025cited by 7position: contributordoi
Affinity Electrophoresis of Proteins for Determination of Ligand Affinity and Exploration of Binding Sites.
2025cited by 2position: contributordoi
Kinetic analysis suggests that malathion at low environmental exposures is not toxic to humans.
2025cited by 1position: contributordoi
Applications of Microbial Organophosphate-Degrading Enzymes to Detoxification of Organophosphorous Compounds for Medical Countermeasures against Poisoning and Environmental Remediation.
2024cited by 8position: contributordoi
Biocatalysis: modern challenges and applications
Russian Chemical Reviews 2024cited by 5position: contributordoi
Pharmacokinetics and fate of free and encapsulated IRD800CW-labelled human BChE intravenously administered in mice.
2024cited by 2position: contributordoi
Human Plasma Butyrylcholinesterase Hydrolyzes Atropine: Kinetic and Molecular Modeling Studies.
2024cited by 2position: contributordoi
Pre-Steady-State and Steady-State Kinetic Analysis of Butyrylcholinesterase-Catalyzed Hydrolysis of Mirabegron, an Arylacylamide Drug.
2024cited by 1position: contributordoi
Polystyrene-Poly(acrylic acid) Block Copolymers for Encapsulation of Butyrylcholinesterase into Injectable Nanoreactors.
2024cited by 1position: contributordoi
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Annals of Oncology 2023cited by 67position: middledoi
Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase.
2023cited by 20position: contributordoi
Partial Reversible Inhibition of Enzymes and Its Metabolic and Pharmaco-Toxicological Implications.
2023cited by 11position: contributordoi
Activation/Inhibition of Cholinesterases by Excess Substrate: Interpretation of the Phenomenological <i>b</i> Factor in Steady-State Rate Equation.
2023cited by 8position: contributordoi
Tuning the Envelope Structure of Enzyme Nanoreactors for In Vivo Detoxification of Organophosphates.
2023cited by 5position: contributordoi
Biomedical Nanosystems for In Vivo Detoxification: From Passive Delivery Systems to Functional Nanodevices and Nanorobots.
2023cited by 3position: contributordoi
Conformational Stability and Denaturation Processes of Proteins Investigated by Electrophoresis under Extreme Conditions.
2022cited by 39position: contributordoi
Enzyme Nanoreactor for <i>In Vivo</i> Detoxification of Organophosphates.
2022cited by 10position: contributordoi
Quantitative Measurements of Pharmacological and Toxicological Activity of Molecules
Chemistry 2022cited by 8position: contributordoi
Kinetic Processes in Enzymatic Nanoreactors for In Vivo Detoxification.
2022cited by 6position: contributordoi
Steady-state kinetic analysis of human cholinesterases over wide concentration ranges of competing substrates.
2022cited by 6position: contributordoi
Organophosphorus poisoning in animals and enzymatic antidotes.
2021cited by 15position: contributordoi
Therapeutic nanoreactors for detoxification of xenobiotics: Concepts, challenges and biotechnological trends with special emphasis to organophosphate bioscavenging.
2021cited by 7position: contributordoi
α-tocopherol, a slow-binding inhibitor of acetylcholinesterase.
2021cited by 3position: contributordoi
Protective effects of m-(tert-butyl) trifluoroacetophenone, a transition state analogue of acetylcholine, against paraoxon toxicity and memory impairments.
2021cited by 2position: contributordoi
Slow-binding reversible inhibitor of acetylcholinesterase with long-lasting action for prophylaxis of organophosphate poisoning.
2020cited by 22position: contributordoi
Slow-binding inhibitors of acetylcholinesterase of medical interest.
2020cited by 19position: contributordoi
Impact of Sucrose as Osmolyte on Molecular Dynamics of Mouse Acetylcholinesterase.
2020cited by 9position: contributordoi
1-(3-<i>Tert</i>-Butylphenyl)-2,2,2-Trifluoroethanone as a Potent Transition-State Analogue Slow-Binding Inhibitor of Human Acetylcholinesterase: Kinetic, MD and QM/MM Studies.
2020cited by 8position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 20 papers (2019–2026)T. N. Pashirova · A.E. Arbuzov Institute of Organic and Physical Chemistry6 papers (2022–2026)Moeava Tehei · Australian National University4 papers (2012–2014) · 4 papers (2012–2014)Sofya Lushchekina · Weizmann Institute of Science4 papers (2020–2022)Zukhra Shaihutdinova · Kazan Federal University4 papers (2024–2026) · 4 papers (2012–2014) · 4 papers (2012–2014) · 4 papers (2012–2014) · 3 papers (2012–2014)Aliya Mukhametgalieva · Kazan Federal University3 papers (2023–2024)Andrey V. Nemtarev · American Chemical Society2 papers (2023–2026)Flynn R. Hill · Australian National University2 papers (2012–2012)Lambert van Eijck · Delft University of Technology2 papers (2012–2012) · 2 papers (2012–2014) · 1 papers (2012–2012) · 1 papers (2012–2012) · 1 papers (2014–2014)Judith Peters · Institut Langevin1 papers (2020–2020)Djaber Tazdaït · Department of Nature and Life Sciences, University of Algiers, Benyoucef Benkhedda, 2 Rue Didouche Mourad, Algeria1 papers (2024–2024)